[Trusopt, a local carboanhydrase inhibitor, in the treatment of glaucoma in children (preliminary report)].
The authors investigated in a group of six children with glaucoma persisting for a long time the possibility to use locally applied carbonic anhydrase inhibitor, 2% dorsolamide hydrochloride in the form of eye drops (TRUSOPT, Merck Co.). In the submitted preliminary study they evaluate the effectiveness of the drug in glaucoma in children very favourably, previous essential treatment with oral acetazolamide could be discontinued in all patients without a deleterious effect. The authors did not encounter any undesirable effects of the drug nor manifestations of intolerance calling for discontinuation of TRUSOPT treatment. This is so far the first communication on TRUSOPT treatment of child glaucoma in the available literature.
Rehůrek
J
J
Klinika dĕtské oftalmologie FDN a LF MU, Brno, CSc.
Vancurová
J
J
D000293:Adolescent; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009883:Ophthalmic Solutions; D013449:Sulfonamides / Q000008:administration & dosage*; D013876:Thiophenes / Q000008:administration & dosage*
D002257:Carbonic Anhydrase Inhibitors; D009883:Ophthalmic Solutions; D013449:Sulfonamides; D013876:Thiophenes; C062765:dorzolamide
Lokální inhibitor karboanhydrázy (TRUSOPT) v lécbĕ glaukomu dĕtského oka. (Predbĕzné sdĕlení).